Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).
The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback